Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPL | P40238 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 2/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 8/20 | 0.36 |
| ▸ | KLKB1 | P03952 | 3/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.35 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.35 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30617732 | 1.00 | MPL (0.40) | MPLL3MBTL1PIM1GRIN2BKLKB1 | |
| SCHEMBL1198409 | 0.94 | L3MBTL1 (0.37) | MPLL3MBTL1PIM1GRIN2BKLKB1 | |
| SCHEMBL1198155 | 0.90 | EIF4E (0.38) | L3MBTL1KLKB1 | |
| SCHEMBL1198005 | 0.89 | GRM2 (0.40) | MPLL3MBTL1PIM1GRIN2BGRIN1 | |
| SCHEMBL12876089 | 0.88 | L3MBTL1 (0.41) | L3MBTL1GRIN2BKLKB1 | |
| SCHEMBL15418750 | 0.86 | MPL (0.38) | MPLPIM1GRIN2BKLKB1KDR | |
| SCHEMBL1198150 | 0.83 | GRM2 (0.40) | L3MBTL1KLKB1 | |
| SCHEMBL1199366 | 0.82 | MPL (0.40) | MPLGRIN2BKLKB1NTRK1 | |
| SCHEMBL20278527 | 0.82 | KLKB1 (0.48) | MPLL3MBTL1KLKB1 | |
| SCHEMBL12876174 | 0.81 | L3MBTL1 (0.41) | L3MBTL1KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220128561-A1 | METHODS TO DETERMINE WHETHER A SUBJECT IS SUITABLE OF BEING TREATED WITH AN AGONIST OF SOLUBLE GYANYLYL CYCLASE (SGC) | BAYER AKTIENGESELLSCHAFT (DE) | 2022-04-28 | — | — | US | claimed |
| EP-3911675-A1 | METHODS TO DETERMINE WHETHER A SUBJECT IS SUITABLE OF BEING TREATED WITH AN AGONIST OF SOLUBLE GUANYLYL CYCLASE (SGC) | Bayer Aktiengesellschaft (DE) | 2021-11-24 | — | — | EP | claimed |
| CN-113330030-A | Method for determining whether a subject is suitable for treatment with an agonist of soluble guanylate cyclase (sGC) | 拜耳公司 | 2021-08-31 | — | — | CN | claimed |
| WO-2020148379-A1 | METHODS TO DETERMINE WHETHER A SUBJECT IS SUITABLE OF BEING TREATED WITH AN AGONIST OF SOLUBLE GUANYLYL CYCLASE (SGC) | BAYER AKTIENGESELLSCHAFT (DE) | 2020-07-23 | — | — | WO | claimed |
| US-20180169095-A1 | THE USE OF SGC STIMULATORS, SGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF DIGITAL ULCERS (DU) CONCOMITANT TO SYSTEMIC SCLEROSIS (SSC) | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-06-21 | — | — | US | claimed |
| EP-3291811-A1 | THE USE OF SGC STIMULATORS, SGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF DIGITAL ULCERS (DU) CONCOMITANT TO SYSTEMIC SCLEROSIS (SSC) | Bayer Pharma Aktiengesellschaft (DE) | 2018-03-14 | — | — | EP | claimed |
| WO-2016177660-A1 | THE USE OF SGC STIMULATORS, SGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF DIGITAL ULCERS (DU) CONCOMITANT TO SYSTEMIC SCLEROSIS (SSC) | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-11-10 | — | — | WO | claimed |
| US-20160158233-A1 | SGC STIMULATORS OR SGC ACTIVATORS AND PDE5 INHIBITORS IN COMBINATION WITH ADDITIONAL TREATMENT FOR THE THERAPY OF CYSTIC FIBROSIS | BAYER PHARMA AKTIENGESELl SCHAFT (DE) | 2016-06-09 | — | — | US | claimed |
| EP-3024455-A1 | SGC STIMULATORS OR SGC ACTIVATORS AND PDE5 INHIBITORS IN COMBINATION WITH ADDITIONAL TREATMENT FOR THE THERAPY OF CYSTIC FIBROSIS | Bayer Pharma Aktiengesellschaft (DE) | 2016-06-01 | — | — | EP | claimed |
| EP-2531187-B1 | sGC STIMULATORS OR sGC ACTIVATORS ALONE AND IN COMBINATION WITH PDE5 INHBITORS FOR THE TREATMENT OF CYSTIC FIBROSIS | ADVERIO PHARMA GMBH (DE) | 2015-08-12 | — | — | EP | claimed |
| WO-2015011086-A1 | SGC STIMULATORS OR SGC ACTIVATORS AND PDE5 INHIBITORS IN COMBINATION WITH ADDITIONAL TREATMENT FOR THE THERAPY OF CYSTIC FIBROSIS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-01-29 | — | — | WO | claimed |
| US-8461348-B2 | Heterocyclic derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-06-11 | — | — | US | claimed |
| US-20130035340-A1 | sGC STIMULATORS OR sGC ACTIVATORS ALONE AND IN COMBINATION WITH PDE5 INHBITORS FOR THE TREATMENT OF CYSTIC FIBROSIS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-02-07 | — | — | US | claimed |
| EP-2531187-A1 | sGC STIMULATORS OR sGC ACTIVATORS ALONE AND IN COMBINATION WITH PDE5 INHBITORS FOR THE TREATMENT OF CYSTIC FIBROSIS | Bayer Intellectual Property GmbH (DE) | 2012-12-12 | — | — | EP | claimed |
| WO-2011095534-A1 | sGC STIMULATORS OR sGC ACTIVATORS ALONE AND IN COMBINATION WITH PDE5 INHBITORS FOR THE TREATMENT OF CYSTIC FIBROSIS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-08-11 | — | — | WO | claimed |
| WO-2011095553-A1 | SGC STIMULATORS OR SGC ACTIVATORS IN COMBINATION WITH PDE5 INHBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-08-11 | — | — | WO | claimed |
| US-20110028493-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-03 | — | — | US | claimed |
| EP-2264017-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2010-12-22 | — | — | EP | claimed |
| US-12427131-B2 | Stimulators and/or activators of soluble guanylate cyclase (sGC) in combination with an inhibitor of neutral endopeptidase (NEP inhibitor) and/or an angiotensin AII antagonist and the use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2025-09-30 | — | — | US | disclosed |
| EP-2264017-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2010-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035340-A1 | sGC STIMULATORS OR sGC ACTIVATORS ALONE AND IN COMBINATION WITH PDE5 INHBITORS FOR THE TREATMENT OF CYSTIC FIBROSIS | PDE5A, PDE3B, PDE3A | MPL 1638/4885L3MBTL1 4548/4885PIM1 1161/4885 |
| US-20180169095-A1 | THE USE OF SGC STIMULATORS, SGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF DIGITAL ULCERS (DU) CONCOMITANT TO SYSTEMIC SCLEROSIS (SSC) | PDE5A, PDE2A, PDE3A | MPL 618/4885L3MBTL1 4426/4885PIM1 2371/4885 |
| US-20160158233-A1 | SGC STIMULATORS OR SGC ACTIVATORS AND PDE5 INHIBITORS IN COMBINATION WITH ADDITIONAL TREATMENT FOR THE THERAPY OF CYSTIC FIBROSIS | PDE5A, PDE3A, GMPS | MPL 1189/4885L3MBTL1 4389/4885PIM1 2759/4885 |
| US-20110028493-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | PDE3B, PDE5A, PDE2A | MPL 1170/4885L3MBTL1 4726/4885PIM1 1856/4885 |
| US-12427131-B2 | Stimulators and/or activators of soluble guanylate cyclase (sGC) in combination with an inhibitor of neutral endopeptidase (NEP inhibitor) and/or an angiotensin AII antagonist and the use thereof | MME, ECE1, REN | MPL 2015/4885L3MBTL1 3762/4885PIM1 1163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.